Dr. Moore on the Prevalence of Ovarian Cancer

Emerging & Promising Clinical Trials in Ovarian Cancer: Learn the LatestПодробнее

Dr. Moore on Unanswered Questions With PARP Inhibitors in Ovarian CancerПодробнее

Improving the Management of Advanced Ovarian CancerПодробнее

Dr. Copeland on the Prevalence of Ovarian Cancer in the United StatesПодробнее

Dr. Moore Discusses Combinations in Ovarian CancerПодробнее

Q&A | Polycystic Ovary Syndrome| Dr Sheela Mane, Sr. OBGYN, Anugraha, BangaloreПодробнее

Dr. Moore on Treatment for Patients With Ovarian Cancer Who Develop Resistance to PARP InhibitorsПодробнее

Dr. Moore on the Impact of SOLO-1 in Ovarian CancerПодробнее

Dr. Moore on the Role of Mirvetuximab Soravtansine in Ovarian CancerПодробнее

Dr. Moore on Early-Phase Data With Mirvetuximab Soravtansine in Ovarian CancerПодробнее

Dr. Moore on Research Evaluating Repeat Exposure to PARP Inhibition in Ovarian CancerПодробнее

Dr. Moore on the NOVA Trial for Ovarian CancerПодробнее

Dr. Moore Discusses Ovarian Preservation in Breast CancerПодробнее

Accurate and timely diagnosis - Dr Liz MooreПодробнее

Dr. Moore on Immunotherapy and PARP Combinations in BRCA-Mutated Ovarian CancerПодробнее

Dr. Moore on the Results of the NOVA Trial in Ovarian CancerПодробнее

Dr. Moore on Challenges With Immunotherapy in Ovarian CancerПодробнее

Dr. Moore on Benefit of Mirvetuximab Soravtansine in Patients With Ovarian CancerПодробнее

Dr. Moore on Safety Profile of Mirvetuximab Soravtansine in Ovarian CancerПодробнее

Challenges With PARP Inhibitors in Ovarian CancerПодробнее

Dr. Moore on Anticipated Impact of the MIRASOL Trial in Platinum-Resistant Ovarian CancerПодробнее